The price-to-earnings ratio for Pfizer Inc (NYSE: PFE) is above average at 16.58x. The 36-month beta value for PFE is also noteworthy at 0.55. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 15 rating it as “hold,” and 1 rating it as “sell.”
The public float for PFE is 5.67B, and at present, short sellers hold a 1.90% of that float. The average trading volume of PFE on May 07, 2025 was 52.09M shares.
PFE) stock’s latest price update
Pfizer Inc (NYSE: PFE)’s stock price has plunge by -4.15relation to previous closing price of 23.87. Nevertheless, the company has seen a -3.83% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-06 that In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
PFE’s Market Performance
PFE’s stock has fallen by -3.83% in the past week, with a monthly drop of -0.39% and a quarterly drop of -11.56%. The volatility ratio for the week is 2.35% while the volatility levels for the last 30 days are 3.54% for Pfizer Inc The simple moving average for the last 20 days is 0.49% for PFE stock, with a simple moving average of -14.88% for the last 200 days.
Analysts’ Opinion of PFE
Many brokerage firms have already submitted their reports for PFE stocks, with Cantor Fitzgerald repeating the rating for PFE by listing it as a “Neutral.” The predicted price for PFE in the upcoming period, according to Cantor Fitzgerald is $24 based on the research report published on April 22, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see PFE reach a price target of $29. The rating they have provided for PFE stocks is “Neutral” according to the report published on December 10th, 2024.
Wolfe Research gave a rating of “Underperform” to PFE, setting the target price at $25 in the report published on November 15th of the previous year.
PFE Trading at -6.56% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.46% of loss for the given period.
Volatility was left at 3.54%, however, over the last 30 days, the volatility rate increased by 2.35%, as shares surge +1.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.15% lower at present.
During the last 5 trading sessions, PFE fell by -3.83%, which changed the moving average for the period of 200-days by -22.99% in comparison to the 20-day moving average, which settled at $22.77. In addition, Pfizer Inc saw -13.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from Dolsten Mikael, who proposed sale 55,000 shares at the price of $23.87 back on May 05 ’25. After this action, Dolsten Mikael now owns shares of Pfizer Inc, valued at $1,312,736 using the latest closing price.
DAMICO JENNIFER B., the SVP & Controller of Pfizer Inc, sale 2,500 shares at $25.93 during a trade that took place back on Mar 04 ’25, which means that DAMICO JENNIFER B. is holding 11,850 shares at $64,825 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.67 for the gross margin
The net margin for Pfizer Inc stands at 0.13. Equity return is now at value 8.62, with 3.67 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 2.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In summary, Pfizer Inc (PFE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
